Profile data is unavailable for this security.
About the company
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.
- Revenue in INR (TTM)71.12bn
- Net income in INR5.84bn
- Incorporated1949
- Employees18.04k
- LocationIPCA Laboratories Ltd125,Kandivli Industrial Estate, Kandivli (WeMUMBAI 400067IndiaIND
- Phone+91 2 262105000
- Fax+91 2 228686613
- Websitehttps://www.ipca.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sai Life Sciences Ltd | 21.70bn | 3.33bn | 193.61bn | 3.40k | 59.13 | -- | 39.35 | 8.92 | 15.47 | 15.47 | 100.85 | -- | -- | -- | -- | 6,380,065.00 | -- | -- | -- | -- | 73.41 | -- | 15.34 | -- | -- | 10.74 | -- | -- | 15.66 | -- | 105.45 | -- | -- | -- |
| Eris Lifesciences Ltd | 30.78bn | 4.31bn | 195.93bn | 3.56k | 44.74 | -- | 25.84 | 6.37 | 31.61 | 31.61 | 225.62 | -- | -- | -- | -- | 8,651,377.00 | -- | 9.98 | -- | 13.50 | 74.64 | 77.74 | 15.28 | 20.85 | -- | 4.06 | -- | -- | 44.02 | 21.92 | -10.24 | 3.48 | 0.4868 | -- |
| Piramal Pharma Ltd | 88.71bn | -1.64bn | 219.61bn | 7.13k | -- | -- | 31.74 | 2.48 | -1.26 | -1.26 | 66.90 | -- | -- | -- | -- | 12,449,300.00 | -- | -- | -- | -- | 64.63 | -- | -1.84 | -- | -- | 0.5519 | -- | -- | 11.99 | -- | 411.39 | -- | -- | -- |
| Astrazeneca Pharma India Ltd | 21.77bn | 2.01bn | 222.98bn | 802.00 | 110.96 | -- | 92.31 | 10.24 | 80.38 | 80.38 | 871.22 | -- | -- | -- | -- | 27,150,250.00 | -- | 11.06 | -- | 18.24 | 42.78 | 49.98 | 9.23 | 9.43 | -- | 78.86 | -- | 38.57 | 32.48 | 15.59 | -28.34 | 9.89 | -34.23 | 100.00 |
| Wockhardt Ltd | 31.51bn | 220.00m | 226.64bn | 2.30k | 1,054.18 | -- | 96.44 | 7.19 | 1.32 | 1.32 | 194.54 | -- | -- | -- | -- | 13,723,870.00 | -- | -4.37 | -- | -7.67 | 65.92 | 56.50 | 0.2539 | -11.98 | -- | 1.23 | -- | -- | 7.65 | 1.15 | 89.85 | -- | 16.19 | -- |
| Pfizer Ltd | 24.82bn | 8.54bn | 230.45bn | 1.60k | 27.00 | -- | 25.24 | 9.28 | 186.60 | 186.60 | 542.67 | -- | -- | -- | -- | 15,533,980.00 | -- | 15.22 | -- | 18.50 | 65.10 | 61.73 | 34.39 | 25.99 | -- | 83.13 | -- | 50.95 | 4.02 | 1.18 | 39.23 | 8.56 | -6.02 | 28.47 |
| Emcure Pharmaceuticals Ltd | 88.50bn | 8.70bn | 282.22bn | 6.73k | 32.43 | -- | 21.70 | 3.19 | 45.91 | 45.91 | 467.02 | -- | -- | -- | -- | 13,148,240.00 | -- | 8.47 | -- | 15.86 | 59.93 | 59.30 | 10.11 | 8.99 | -- | 30.68 | -- | 0.00 | 18.59 | 9.36 | 36.76 | 52.13 | 21.35 | -- |
| Gland Pharma Ltd | 61.13bn | 8.47bn | 293.40bn | 4.35k | 34.63 | -- | 23.32 | 4.80 | 51.42 | 51.42 | 371.01 | -- | -- | -- | -- | 14,049,110.00 | -- | 10.77 | -- | 11.98 | 65.00 | 57.00 | 13.86 | 19.59 | -- | 34.31 | -- | 14.03 | -0.8512 | 16.36 | -9.57 | -2.00 | 15.15 | -- |
| J B Chemicals and Pharmaceuticals Ltd | 41.93bn | 7.54bn | 303.69bn | 5.52k | 39.88 | -- | 32.56 | 7.24 | 47.44 | 47.44 | 263.86 | -- | -- | -- | -- | 7,600,215.00 | -- | 15.91 | -- | 19.18 | 67.95 | 62.00 | 17.98 | 16.36 | -- | 164.76 | -- | 33.55 | 12.45 | 17.16 | 19.35 | 19.53 | 10.52 | 23.03 |
| Ajanta Pharma Ltd | 52.02bn | 10.15bn | 364.82bn | 9.63k | 35.96 | -- | 30.86 | 7.01 | 81.21 | 81.21 | 416.34 | -- | -- | -- | -- | 5,402,607.00 | -- | 17.31 | -- | 21.48 | 77.65 | 73.83 | 19.50 | 19.60 | -- | 96.70 | -- | 33.78 | 10.44 | 12.43 | 12.77 | 14.50 | 5.84 | 26.43 |
| IPCA Laboratories Ltd | 71.12bn | 5.84bn | 376.85bn | 18.04k | 64.57 | -- | 27.73 | 5.30 | 23.00 | 35.86 | -- | -- | -- | -- | -- | 3,941,717.00 | -- | 9.16 | -- | 12.39 | 70.13 | 60.24 | 13.33 | 11.25 | -- | 14.07 | -- | 13.42 | 16.02 | 13.97 | 34.77 | 4.00 | 20.42 | 9.86 |
| Anthem BioSciences Ltd | 19.97bn | 4.85bn | 387.55bn | 2.06k | 80.31 | -- | 63.58 | 19.41 | 8.59 | 8.59 | 35.41 | -- | -- | -- | -- | 9,682,764.00 | -- | -- | -- | -- | 61.25 | -- | 24.27 | -- | -- | -- | -- | -- | 29.96 | -- | 22.86 | -- | -- | -- |
| GlaxoSmithKline Pharmaceuticals Ltd | 38.01bn | 10.21bn | 439.51bn | 3.11k | 43.05 | -- | 40.36 | 11.56 | 60.26 | 60.26 | 224.34 | -- | -- | -- | -- | 12,209,250.00 | -- | 15.30 | -- | 25.66 | 64.24 | 56.70 | 26.86 | 16.77 | -- | 452.52 | -- | 144.35 | 8.56 | 3.06 | 57.23 | 53.14 | -31.03 | 16.00 |
| Laurus Labs Ltd | 67.22bn | 8.43bn | 545.58bn | 6.17k | 64.74 | -- | 41.64 | 8.12 | 15.61 | 15.61 | 124.44 | -- | -- | -- | -- | 10,899,350.00 | -- | 8.88 | -- | 14.31 | 58.67 | 48.18 | 12.52 | 11.88 | -- | 7.10 | -- | 13.79 | 10.18 | 14.42 | 123.18 | 7.02 | 23.60 | -- |
| Abbott India Ltd | 68.24bn | 15.24bn | 562.26bn | 3.66k | 36.89 | -- | 35.16 | 8.24 | 717.26 | 717.26 | 3,211.47 | -- | -- | -- | -- | 18,650,260.00 | -- | 22.42 | -- | 30.42 | 46.61 | 44.59 | 22.33 | 18.83 | -- | 79.05 | -- | 73.99 | 9.58 | 9.38 | 17.75 | 18.99 | 27.31 | 34.73 |
| Glenmark Pharmaceuticals Ltd | 164.68bn | 10.65bn | 563.72bn | 13.48k | 52.95 | -- | 34.89 | 3.42 | 37.72 | 37.72 | 583.32 | -- | -- | -- | -- | 12,219,440.00 | -- | 1.33 | -- | 1.92 | 71.68 | 60.15 | 6.47 | 1.82 | -- | 16.41 | -- | 39.62 | 12.77 | 4.60 | 155.14 | 6.18 | -4.24 | 0.00 |
Data as of Feb 16 2026. Currency figures normalised to IPCA Laboratories Ltd's reporting currency: Indian Rupee INR
34.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Jun 2025 | 22.97m | 9.05% |
| DSP Asset Managers Pvt. Ltd.as of 31 Jan 2026 | 15.72m | 6.20% |
| Kotak Mahindra Asset Management Co. Ltd.as of 30 Jun 2025 | 15.34m | 6.05% |
| SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 30 Jun 2025 | 8.37m | 3.30% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Dec 2025 | 7.08m | 2.79% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 5.42m | 2.14% |
| HDFC Life Insurance Co. Ltd. (Investment Portfolio)as of 31 Jan 2026 | 4.06m | 1.60% |
| Kotak Mahindra Asset Management (Singapore) Pte Ltd.as of 31 Dec 2024 | 3.41m | 1.34% |
| MFS International Singapore Pte Ltd.as of 31 Dec 2025 | 2.68m | 1.06% |
| Axis Asset Management Co. Ltd.as of 31 Jan 2026 | 2.64m | 1.04% |
More ▼
Data from 31 Oct 2025 - 10 Feb 2026Source: FactSet Research Systems Inc.
